Therefore, we would choose between two FDA‐approved drugs for R/R PTCL, romidepsin, and brentuximab vedotin, based on CD30 positivity and combine them with salvage chemotherapy (ICE). This evidence concerns the gene TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma.